These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33816696)

  • 1. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
    Shen M; Liu S; Stoyanova T
    Am J Clin Exp Urol; 2021; 9(1):73-87. PubMed ID: 33816696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
    Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
    Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
    Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
    Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 9. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 10. Trop2-targeted therapy in breast cancer.
    Hu Y; Zhu Y; Qi D; Tang C; Zhang W
    Biomark Res; 2024 Aug; 12(1):82. PubMed ID: 39135109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
    Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
    Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
    Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
    Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
    Coates JT; Sun S; Leshchiner I; Thimmiah N; Martin EE; McLoughlin D; Danysh BP; Slowik K; Jacobs RA; Rhrissorrakrai K; Utro F; Levovitz C; Denault E; Walmsley CS; Kambadakone A; Stone JR; Isakoff SJ; Parida L; Juric D; Getz G; Bardia A; Ellisen LW
    Cancer Discov; 2021 Oct; 11(10):2436-2445. PubMed ID: 34404686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trop2: Jack of All Trades, Master of None.
    Lenárt S; Lenárt P; Šmarda J; Remšík J; Souček K; Beneš P
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33187148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.
    Shvartsur A; Bonavida B
    Genes Cancer; 2015 Mar; 6(3-4):84-105. PubMed ID: 26000093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.